Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

M. D'Incalci, N. Badri, C. M. Galmarini, P. Allavena

Research output: Contribution to journalArticlepeer-review


Trabectedin is the first marine-derived anti-neoplastic drug approved for the treatment of advanced soft tissue sarcoma and, in combination with pegylated liposomal doxorubicin, for the treatment of patients with relapsed platinum-sensitive ovarian cancer. From the beginning of its development, trabectedin showed some peculiar properties that clearly distinguished it from other anti-cancer drugs. In this mini-review, we will outline the current state of knowledge regarding the mode of action of trabectedin, which appears to represent a new class of anti-neoplastic drugs acting both on cancer cells and on the tumour microenvironment.

Original languageEnglish
Pages (from-to)646-650
Number of pages5
JournalBritish Journal of Cancer
Issue number4
Publication statusPublished - Aug 12 2014


  • macrophages
  • microenvironment
  • sarcoma
  • trabectedin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Trabectedin, a drug acting on both cancer cells and the tumour microenvironment'. Together they form a unique fingerprint.

Cite this